Abstract
Prognosis of unresectable pancreatic cancer (uPC) remains poor with short overall survival (OS) and no robust predictive marker of response. KRAS mutation is observed in 90% of PCs and GNAS mutation in about 60% still poorly studied. KRAS-mutated circulating tumor DNA (KRAS-mut ctDNA) emerges as prognostic marker but whether ctDNA kinetics is a reliable predictor of response to chemotherapy (CT) remains uncertain. KRASCIPANC study evaluated KRAS-mut ctDNA kinetic as early predictor of response to 1st line CT in uPCs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
